Placebo Metformin ***p < vs placebo

Slides:

Advertisements

Similar presentations

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes A double-tracer study.

Advertisements

Philip J. Barter, et al. Circulation 2011;124:

PPAR  activation & lipid metabolism. Diabetic dyslipidaemia Lipid profiles and hyperinsulinaemia in newly diagnosed type 2 diabetic patients Niskanen.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 7.

Diabetes Prevention Program (DPP)

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association (ADA)

Increased Lipolysis Impaired Insulin Secretion TZDs GLP-1 analogues

Contributions to Type 2 Diabetes. Glucose in balance meal Time in minutes Blood glucose levels, mg/dL Insulin levels, uU/mL Glucagon.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 4.

DIABETES JOURNAL CLUB MARCH 15, 2012 MARGAUX AÑEL-TIANGCO, MD.

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose- Ranging.

Fig. 2. Change in (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG). Group A: oral hypoglycemic agents (OHAs; sulfonylurea+metformin.

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.

James Thrasher, MD The American Journal of Medicine

Copyright © 2015 by the American Osteopathic Association.

Volume 352, Issue 9131, Pages (September 1998)

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive.

Plant stanol esters in low-fat yogurt reduces total and low-density lipoprotein cholesterol and low-density lipoprotein oxidation in normocholesterolemic.

Copyright © 2015 by the American Osteopathic Association.

Robert Vigersky, Maneesh Shrivastav

Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD

Copyright © 2015 by the American Osteopathic Association.

Mancia and Grassi (2018) Diabetologia DOI /s

Nat. Rev. Nephrol. doi: /nrneph

with undiagnosed diabetes mellitus by three diagnostic criteria

James H. Liu, MD The American Journal of Medicine

Figure 4 Effect of dapagliflozin on HbA1c and body weight

Volume 70, Issue 8, Pages (October 2006)

James Thrasher, MD The American Journal of Medicine

Athena Philis-Tsimikas, MD The American Journal of Medicine

George Dailey, MD Mayo Clinic Proceedings

Effects of highly concentrated SFN provided as BSE in T2D patients

Depiction of the elements of decision making used to determine appropriate efforts to achieve glycemic targets. Depiction of the elements of decision making.

Depicted are patient and disease factors used to determine optimal A1C targets. Depicted are patient and disease factors used to determine optimal A1C.

Individualizing Insulin Therapy in the Management of Type 2 Diabetes

Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD

Bisphosphonate exposure and Atypical Femoral Fractures

Dandan Wang et al. BTS 2018;3: Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. Change in HbA1c and weight compared with baseline.

Receiver operating characteristic analyses showing area under the curves with reference to 2-hour OGTT (A,B) and fasting plasma glucose (C,D). HbA1c, glycated.

Medical management of fecal incontinence

The proportion of patients confronted with a cardiovascular risk factor (CVRF) they were previously unaware of, referring to the instrument based tests.

Effects of Niacin on Glucose Control in Patients With Dyslipidemia

Fig. 3. (A) Least-squares (LS) mean difference in glycosylated hemoglobin (HbA1c) from baseline, and (B) LS mean difference in HbA1c from baseline over.

Effect of metformin on glycemic control, insulin secretion, and insulin sensitivity in T2D. Effect of metformin on glycemic control, insulin secretion,

TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

A: The change of plasma glucose in opioid μ-receptor knockout diabetic mice and wild-type controls receiving an oral intake of metformin (100 mg/kg). A:

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

Illustration of a trial design to help evaluate the clinical accuracy of a test of ischaemia. Illustration of a trial design to help evaluate the clinical.

Observed RW, modeled, and published trial estimates of HbA1c change from baseline. Observed RW, modeled, and published trial estimates of HbA1c change.

Fig. 2. Changes in glycosylated hemoglobin (HbA1c) levels

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

Multivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary heart disease (CHD), stroke, and all-cause mortality according to fasting.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Glycemic control and body weight over 52 weeks.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 7.

Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH.

PHOENIX I: PASI 75 Response After 12 Weeks

Effects of highly concentrated SFN provided as BSE in T2D patients

Elevated blood glucose vs time.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.

Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Presentation transcript:

Mean changes in fasting plasma glucose and HbA1c in the Multicenter Metformin Study, Protocol 1 Placebo Metformin ***p < 0.001 vs placebo Sanchez-Rangel and Inzucchi (2017) Diabetologia DOI 10.1007/s00125-017-4336-x © 1995 Massachusetts Medical Society. Adapted with permission from DeFronzo et al

Fasting plasma glucose Placebo-subtracted adjusted mean changes in fasting plasma glucose and HbA1c over 11 weeks in 451 patients with type 2 diabetes randomised to metformin or placebo Fasting plasma glucose HbA1c Sanchez-Rangel and Inzucchi (2017) Diabetologia DOI 10.1007/s00125-017-4336-x © 1997 Elsevier, adapted with permission from Garber et al †p = 0.054, **p < 0.01 and ***p < 0.001 vs placebo

Mean changes in fasting plasma glucose and HbA1c in the Multicenter Metformin Study, Protocol 2 Glibenclamide + metformin Glibenclamide Switched from glibenclamide to metformin **p < 0.01, ***p < 0.001 metformin vs glibenclamide; †††p < 0.001 combination therapy vs glibenclamide Sanchez-Rangel and Inzucchi (2017) Diabetologia DOI 10.1007/s00125-017-4336-x © 1995 Massachusetts Medical Society. Adapted with permission from DeFronzo et al